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Post-translational modification of proteins and peptides by ubiquitin, a highly evolutionarily conserved 76 residue protein, and ubiquitin-like
modifiers has emerged as a major regulatory mechanism in various cellular activities. Eukaryotic viruses are known to modulate protein
ubiquitination to their advantage in various ways. At the same time, the evidence for the importance of deubiquitination as a viral target also is
growing. This review centers on known viral interactions with protein deubiquitination, on viral enzymes for which deubiquitinating activities
were recently demonstrated, and on the roles of viral ubiquitin-like sequences.
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Post-translational modification of proteins and peptides by
ubiquitin (Ub), a highly evolutionarily conserved 76 residue
protein, and ubiquitin-like modifiers (Ubls) (Fig. 1) has emerged
as a major regulatory mechanism in various cellular activities
including signal transduction, transcription, membrane protein
trafficking, nuclear transport, autophagy, and immune responses
(d'Azzo et al., 2005; Haglund and Dikic, 2005; Welchman et al.,
2005). Protein modifications by Ub and Ubls, such as Nedd8,
ISG15, and SUMO, modulate protein–protein interactions
(Kerscher et al., 2006), while ubiquitin-like Atg8 homologs
become lipidated and attached to cellular membranes (Tanida et
al., 2004). Ub and most Ubls are produced as precursor proteins,
and only carboxy-terminal processing after recognition
sequence motifs by deubiquitinating enzymes (DUBs) generates
the active modifiers (Amerik and Hochstrasser, 2004). Con-
jugations of Ub and Ubls to their targets relies on analogous
enzymatic cascades comprising the sequential action of three
enzymes (Passmore and Barford, 2004): a modifier activating
enzyme (E1), one of several modifier carrier enzymes (E2s),
and a member of the large and diverse group of modifier-target⁎ Fax: +1 514 496 5143.
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doi:10.1016/j.virol.2006.12.035ligases (E3s), which chiefly determine target specificity. The
enzymatic trio transfers the carboxy terminal glycine of Ub to
the epsilon-NH2 group of an internal lysine residue of the
target protein, or less often to its terminal amino group. In
contrast to the known Ubl modifications, Ub can further be
assembled into polymeric chains (polyubiquitination). One out
of five internal lysine residues at position 6, 11, 29, 48, and 63
of Ub, but mostly lysine-48 or lysine-63, is used for the
attachment of additional Ub units.
While attachment of at least four lysine-48 linked Ub
molecules usually promotes the degradation of a protein by the
Ub-proteasome system (UPS), the most important machinery
for the degradation of cytoplasmic and nuclear proteins, chain
formation via other lysine residues, or conjugation of individual
Ub molecules mediates largely non-proteolytic functions of Ub
(Ciechanover, 2006). Ub and Ubl modifications are reversed
through the isopeptidase activities of DUBs (Fig. 1), with most
studied DUBs deconjugating only a small number of targets
(Nijman et al., 2005). In fact, deubiquitination, a term used here
inclusive of Ub and Ubl deconjugation, is an emerging
regulatory process in signaling pathways, chromatin structure,
endocytosis, and apoptosis (Nijman et al., 2005) and is
important for physiological activities including neuronal
function, development, and immunity (Evans, 2005).
Viruses of eukaryotes are known to take advantage of protein
ubiquitination in various ways. Entry or release of differentc. All rights reserved.
Fig. 1. General schematic for Ubl conjugation and deconjugation and points of viral interference. Proteolytic maturation of Ubl (including Ub) precursor proteins by
DUBs (step 1) exposes a new C-terminus in the modifier, which is then activated by E1 in an ATP-dependent manner (step 2) and next transferred to the E2 (step 3). An
E3 generally recognizes the target protein (step 4) and facilitates the ligation of the Ubl to it (step 5), altering its protein interaction repertory and thereby its function.
Polyubiquitination as a particular example of Ubl modification of a protein can lead to its proteasomal degradation. Ubl deconjugation by DUBs reversely regulates
target protein function and, additionally, replenishes the pool of free Ubl (step 6). Points of viral interference are marked (*). Viruses are known to intervene with the
Ub conjugation pathway (at steps 4 and 5, see text), but also target Ubl deconjugation (step 6), inclusively referred to as deubiquitination, which is the principal theme
of this review. Viruses may also interfere with Ubl precursor processing (step 1), as suggested by the ability of some viral DUBs to process the ISG15 precursor protein
(see text).
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or on certain cellular E3s (Banks et al., 2003; Bieniasz, 2006;
Ros and Kempf, 2004; Yu and Lai, 2005). What is more, many
viruses manipulate protein ubiquitination in order to overcome
host cell defense mechanisms, including apoptosis, the type 1
interferon (IFN) response, and major histocompatibility com-
plex (MHC) class 1 antigen presentation. To this end, numerous
viruses encode proteins that redirect cellular E3s of the UPS to
proteins with antiviral activity (Fig. 1, step 4), including for
example the tumor suppressor protein p53 (induction of apo-
ptosis) and the signal transducers and activators of transcription
(IFN response). Alternatively, some viruses express their own
E3s (Fig. 1, step5), which commit cellular defense proteins,
such as p53 or MHC class 1 molecules, to degradation. Such
viral strategies were reviewed recently by Shackelford and
Pagano (2005), Gao and Luo (2006), and Barry and Früh (2006)
and are not considered here in detail.
Different from ubiquitination, only few examples for the
targeting of protein deubiquitination (Fig. 1, step 6) by viruses
have been described to date. They include the potential recruit-
ment of DUBs for the stabilization of β-catenin in Epstein–Barr
virus (EBV)-infected B cells (Ovaa et al., 2004; Shackelford
et al., 2003), and the specific targeting of the cellular DUB
ubiquitin-specific protease 7 (USP7) by the Epstein–Barr
nuclear antigen 1 (EBNA1) and the herpes simplex virus type
1 (HSV-1) regulatory protein ICP0 (Everett et al., 1997;
Holowaty and Frappier, 2004). Despite the compelling bio-
chemical evidence for the specificity of these two interactions,the importance of viral targeting of USP7 remains vague. The
possibility that modulation of deubiquitination is, nevertheless,
a more common viral strategy has gained support by the recent
in vitro demonstration of deubiquitinating activities for three
viral enzymes: the adenovirus protease adenain (Balakirev et
al., 2002), the papain-like protease (PLpro) of severe acute
respiratory syndrome coronavirus (SARS-CoV) (Barretto et al.,
2005; Lindner et al., 2005), and a protease domain contained in
the N-terminal fragment of the large tegument protein UL36
(UL36USP) from several herpesviruses, namely, HSV-1, EBV,
and mouse and human cytomegalovirus (MCMV and HCMV)
(Kattenhorn et al., 2005; Schlieker et al., 2005; Wang et al.,
2006). However, the roles of these deubiquitinating activities
during virus infection remain elusive. Here, the known viral
interactions with protein deubiquitination are reviewed, and
potential roles of viral DUBs are considered.
Deubiquitinating enzymes
The majority of the DUBs from all kingdoms of life
(excluding archaea), including the known and predicted viral
enzymes, represent cysteine protease homologs, with the
remainder forming a separate family of metalloproteases
(Rawlings et al., 2004). At least six structural classes (families)
of cysteine protease DUBs have been identified: the ubiquitin-
specific protease (USP), autophagin (ATG), ubiquitin C-
terminal hydrolase (UCH), ovarian tumor-related protease
(OTU), Josephin-domain protease (JD), and ubiquitin-like
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strasser, 2004; Nijman et al., 2005; Sulea et al., 2006). They all
feature structural variations of the papain fold and display
canonical papain-like spatial arrangement of catalytic centers.
Many are further characterized by additional variable amino-
and/or carboxy-terminal sequences, for which a growing
number of structures and functions, including localization,
substrate recognition, and/or activation of catalytic activity, are
being reported (Nijman et al., 2005; Reyes-Turcu et al., 2006;
Sulea et al., 2006).
Despite recent advances in the understanding of DUB
structure–function relationships (Amerik and Hochstrasser,
2004; Nijman et al., 2005; Sulea et al., 2006), inference of
biological importance for uncharacterized DUBs from sequence
information alone remains challenging. The human genome
encodes around 90 cysteine protease DUBs and 12 metallo-
protease DUBs (Rawlings et al., 2004). The number of
catalytically active human cysteine protease DUBs, inclusive
of putative alternative splice isoforms, amounts to over 100. In
order to further the functional characterization of DUBs on a
large scale, Ploegh and co-workers synthesized specific probes
for the proteomic profiling of cysteine protease DUB activities
(Borodovsky et al., 2002). They used an intein-based chemical
ligation method to modify the free C-terminus of a hemagglu-
tinin (HA)-tagged Ub with a series of thiol-reactive groups,
such as vinylmethylsulfone (VME) or bromoethylamine. After
incubation of cellular lysates with some of these active site-
directed suicide substrates and subsequent anti-HA immuno-
precipitation, tandem mass spectrometry facilitated the simul-
taneous identification of multiple DUBs and some associated
proteins (Borodovsky et al., 2002). HAUbVME exhibited the
broadest reactivity, and, in the following, was used to detect
active cysteine protease DUBs and associated proteins in EBV-
infected B cells (Ovaa et al., 2004; Shackelford et al., 2003),
and human papillomavirus (HPV)-infected cervical carcinoma
cells as well as HPV E6/E7 immortalized keratinocytes (Rolén
et al., 2006).
β-Catenin stabilization in Epstein–Barr virus infection
In a study by Ovaa et al. (2004), lymphoblastoid transforma-
tion of freshly isolated B cells by in vitro EBV infection led to
an increase in the activities of six cellular DUBs, identified as
UCH37, UCH-L3, UCH-L1, USP7, USP9X, and USP15, at
different times postinfection. Interestingly, USP9X was pre-
viously shown to interact with the bifunctional armadillo repeat
protein β-catenin in vitro as well as in cultured epithelial cells
and was able to stabilize β-catenin in these cells (Taya et al.,
1999). β-Catenin is further known to be stabilized in latency
type III EBV-transformed B cells (see below).
β-Catenin is a component of cell-cell adherens junctions. At
the same time, a low-level cytoplasmic pool of this protein
functions in canonical Wnt signaling (reviewed by Brembeck et
al., 2006). In the absence of Wnt signaling, cytoplasmic β-
catenin is continuously phosphorylated by casein kinase
followed by glycogen synthase kinase 3-β, which together
with the two scaffold proteins axin and the adenomatosispolyposis coli tumor-suppressor protein constitute the so-called
degradation complex. These consecutive phosphorylations
events initiate the polyubiquitination of β-catenin by a Ub
ligase complex, known as Skp1/cullin/F box proteinβ-TrCP
(SCFβ-TrCP) (Liu et al., 2001, and references therein), and its
rapid proteasomal degradation. Binding of the Wnt ligand to its
cell surface receptors is thought to trigger a series of
phosphorylation events that result amongst others in the
degradation of axin, causing disassembly of the above-
mentioned degradation complex and consequently the stabiliza-
tion of β-catenin which then accumulates in the nucleus. Here,
β-catenin acts as a coactivator of Wnt target genes that regulate
cellular proliferation and differentiation during animal devel-
opment and tissue homeostasis (Städeli et al., 2006).
β-Catenin stabilization in latency type III EBV-transformed
B cells occurs by mechanisms that involve EBV latent
membrane proteins 1 (LMP1) and 2A (LMP2A) (Hayward et
al., 2006). This does, however, not necessarily entail its nuclear
accumulation, indicating that effects of EBV induced β-catenin
stabilization are dependent on the cellular context and in
lymphoid cells may be distinct from Wnt activation (Morrison
et al., 2004). Lately, Pagano and coworkers identified LMP1 as
a transcriptional down-regulator of another Ub ligase complex
that targets β-catenin for proteasomal degradation and is called
seven in absentia homolog-1 (Jang et al., 2005). In any event,
the observed up-regulation of DUBs in EBV transformed B
cells by Ovaa et al. (2004), together with the almost
simultaneous demonstration that β-catenin in the type III
latently infected B cell line Sav III exists in a complex with
active, yet unidentified DUBs by Shackelford et al. (2003),
strengthens the possibility that DUBs contribute to EBV
induced β-catenin stabilization.
Viral targeting of ubiquitin-specific protease 7
USP7 is an evolutionary conserved mammalian DUB of the
USP family, which was originally identified by its ability to
bind to two different herpesviral proteins, namely, EBNA1 of
EBV, and the HSV-1 regulatory protein ICP0 for which it has
also been coined herpes virus-associated ubiquitin-specific
protease (HAUSP) (Everett et al., 1997; Holowaty and Frappier,
2004). USP7 displays debranching activity against lysine-48
linked polyubiquitin chains and was shown to play an important
part in the dynamic regulation of nuclear p53 turnover (Brooks
and Gu, 2006; Cheon and Baek, 2006).
Ubiquitin-specific protease 7 and the p53-MDM2 pathway
In unstressed cells, p53 is constitutively polyubiquitinated,
which leads to its proteasomal degradation, keeping p53 levels
low (Gomez-Lazaro et al., 2004). p53 levels dramatically
increase upon various types of stress, including viral infection,
triggering either growth arrest or apoptosis. Virus mediated
gain of p53 ubiquitinating activity as a means of apoptosis
avoidance was already mentioned above. Expression of USP7,
the target protein of EBNA1 and ICP0, however, effectively
promotes increased levels of p53 by antagonizing proteasomal
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As may be expected, partial reduction of USP7 levels by RNA
interference (RNAi) was shown to destabilize p53 (Li et al.,
2004). With the collaboration of the adapter protein Daxx
(death domain associated protein) (Tang et al., 2006), USP7
also deubiquitinates the mouse double minute 2 (MDM2)
oncogene, one of several E3s that mediate p53 proteasomal
degradation. This counteracts autoubiquitination of MDM2 and
its proteasomal degradation (Li et al., 2004). In fact, a genetic
knockout of USP7 caused depletion of MDM2 and, despite the
aforementioned rescue effect of USP7 on p53, effectively
stabilized p53 (Cummins et al., 2004; Li et al., 2004). Brooks
and Gu (2006) have recently proposed that the predominant
role of MDM2 during cellular stress is to ubiquitinate p53, and
to keep its levels in check in order to maintain growth arrest
while avoiding default execution of the apoptotic program and
thereby to afford cell survival in the event of successful cellular
repair and overcoming of the original challenge. In view of
these activities, USP7 appears to be well-positioned to relay
signals that regulate the p53-MDM2 pathway (Fig. 2). But it
also becomes clear that the possible reduction of p53 levels
through viral inhibition of USP7 would likely need to be well-
balanced in order not to achieve the opposite. Recent structure–
functional studies on the EBV protein EBNA1 have brought to
light how this protein may accomplish this and are outlined in
the following. The role of the ICP0-USP7 interaction in p53
metabolism during HSV-1 infection has as yet proven complex
to delineated (see below).
Epstein–Barr nuclear antigen 1
For a long time, EBNA1 has been known as a regulator of
both transcription and replication of the EBV genome, as wellFig. 2. Model for regulation of the p53-MDM2 pathway by USP7 and interferenc
ubiquitination of p53 leading to proteasomal degradation in both cases. Deubiquitinat
USP7 to MDM2. Partial reduction of USP7 activity by RNAi destabilizes p53 throu
commits MDM2 to proteasomal degradation thus leading to an important reduction in
EBNA1, MDM2, and p53 compete for same binding site on USP7, with affinities
selectivity and contribute twofold to p53 destabilization. By blocking the deubiquitina
sufficient levels of MDM2 that maintain p53 ubiquitination.as being required for the segregation of EBV genomes with
chromosomes during mitosis (Frappier, 2004; Wang and
Sugden, 2005). EBNA1 is essential for viral persistence,
promotes cellular immortalization and is found consistently
expressed in EBV-associated human malignancies including
Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyn-
geal carcinoma. Functional studies by Saridakis et al. (2005)
have indicated that an interaction of transfected EBNA1 with
USP7 fosters cellular degradation of p53, presumably by
preventing p53 deubiquitination through USP7, and confers
apoptosis resistance to UV-irradiated cells. Structural analyses
from the laboratories of Shi and Frappier have recently provided
insight into the molecular mechanism by which EBNA1
modulates p53 turnover and likely contributes to the anti-
apoptotic and survival factor function of EBNA1 in vivo.
Crystal structures for short EBNA1, p53, and MDM2 peptides,
respectively, in complex with the N-terminal tumor necrosis
factor-receptor associated factor (TRAF)-like domain of USP7
show that these three proteins use a consensus tetrapeptide
recognition sequence to engage in structurally conserved
contacts with the same surface groove of the TRAF-like
domain of USP7 (Hu et al., 2006; Saridakis et al., 2005; Sheng
et al., 2006). The buried contact surface areas and extent of
directed interactions, as well as the measured binding affinities
of corresponding peptides to the USP7 TRAF-like domain
increase in the order of p53<MDM2<EBNA1 (Hu et al., 2006;
Sheng et al., 2006). It appears that the competitive binding to
USP7 of EBNA1 versus p53 and MDM2 prevents deubiqui-
tination of the lowest affinity binder (p53) sufficiently to reduce
cellular p53 levels, while it permits deubiquitination of the
intermediate binder (MDM2) to continue, avoiding MDM2
depletion and p53 stabilization, as observed in the USP7
knockout (Fig. 2). Otherwise, i.e., in case MDM2 levels alsoe by EBNA1. The E3 enzyme MDM2 catalyses both autoubiquitination and
ion by USP7 stabilizes p53 and MDM2, with the adaptor protein Daxx directing
gh reduced deubiquitination. Contrarily, genetic knockout of USP7 increasingly
p53 ubiquitination and, indirectly, effective p53 stabilization. The EBV protein
decreasing in this order. Hence, inhibition of USP7 by EBNA1 may exhibit
tion of p53 more efficiently than the deubiquitination of MDM2, it may allow for
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remaining E3s for p53 (Brooks and Gu, 2006) may play an
important role in keeping p53 levels low in EBV-infected cells.
Herpes simplex virus regulatory protein ICP0
The immediate–early HSV-1 gene product ICP0 is required
for efficient initiation of lytic infection by stimulating the
reactivation of quiescent viral genomes (Hagglund and Roiz-
man, 2004). ICP0 functions as an E3 whose putative in vivo
targets include p53. Early in HSV-1 infection, ICP0 associates
with nuclear domain 10 (ND10), nuclear substructures that are
found juxtaposed to the genomes of many DNA viruses
including herpesviruses and adenoviruses (Everett, 2006).
ND10 have been implicated in DNA repair, the IFN response,
and the regulation of p53 activity (Everett, 2006; Takahashi et
al., 2004) and might be preferred sites of transcription and
replication of DNA viral genomes (Ching et al., 2005). ICP0
induces the proteasomal degradation of the ND10 organizing
promyelocytic leukemia (PML) protein and promotes rapid
dispersal of ND10 (Everett, 2006). This has been proposed to
alleviate PML protein mediated anti-HSV-1 effects of IFN
(Chee et al., 2003). Recent results by Everett et al. (2006),
obtained by the use of RNAi to reduce PML levels, indeed
argue for the contribution of PML to a cellular antiviral
repression mechanism that is countered by ICP0.
Everett and coworkers (1997) had previously demonstrated
that ICP0 increases the proportion of USP7 localized to ND10.
Contrary to EBNA1, p53, and MDM2, the binding of ICP0 to
USP7 was mapped to a domain of unknown structure, located
C-terminally to the catalytic core domain of USP7 (Holowaty et
al., 2003). Possible effects of ICP0 on p53 metabolism were
shown not to depend on the interaction of ICP0 with USP7 but
on the particular cell type under investigation (Boutell and
Everett, 2004). Instead, the significance of ICP0 binding to
USP7 possibly lies in the ability of USP7 to counteract auto-
ubiquitination of ICP0 and to protect it from proteasomal
degradation (Canning et al., 2004). Although USP7 is con-
versely ubiquitinated and marked for proteasomal degradation
by ICP0, the biological net effect of the reciprocal activities
between ICP0 and USP7 is thought to be the stabilization of
ICP0 early during HSV-1 lytic infection or reactivation from
latency, when ICP0 levels are low (Boutell et al., 2005).
Interestingly, the aforementioned USP7-MDM2 adaptor protein
Daxx (Tang et al., 2006) is a major ND10 component (Everett et
al., 2006), raising the question whether it also has an adaptor
function for USP7 in this nuclear compartment.
Viral deubiquitinating activities
Deubiquitinating activities for viral enzymes have directly
been demonstrated for the adenovirus protease adenain, SARS-
CoV PLpro, and herpesviral UL36USP. Structural aspects of
these specificities have been reviewed recently by Sulea et al.
(2006). In the following, potential roles for these confirmed
viral DUBs are considered against the background of their
established functions and properties.Adenovirus protease adenain
During adenovirus infection, adenain is first made in an
essentially inactive form of 23 kDa which localizes to both the
cytoplasm and the nucleus (reviewed by Mangel et al., 2003). In
the nucleus, binding to viral DNA partially activates the enzyme
inside nascent virions, allowing it to cleave an eleven amino
acid peptide, named pVIc, from the precursor of the viral DNA
binding capsid protein VI (pVI). pVIc binding fully activates
adenain, and the peptidic cofactor becomes eventually dis-
ulphide-linked to the enzyme. Activated adenain is thought to
subsequently complete the proteolytic maturation of altogether
six virus capsid precursor proteins inside the virion. The
stepwise activation of adenain by viral DNA and pVIc prevents
precursor protein cleavage before virion assembly and the ge-
neration of immature capsids. Maturation of the capsid proteins
is important for their ability to promote low-pH activated endo-
somal lysis and cytoplasmic entry of viral capsids during the
next infection cycle (Cotten and Weber, 1995).
Cytoplasmic adenain is believed to contribute to cell lysis
and release of virions by the cleavage of cytoskeletal proteins,
including cytokeratin 18 and actin. In contrast to nuclear
adenain, the cytoplasmic form has no access to either of the two
capsid bound viral cofactors, viral DNA and pVIc. Instead, the
C-terminal sequence of actin, which is highly homologous to
pVIc, efficiently replaces pVIc acting as a cellular cofactor
(Brown and Mangel, 2004). Within the extracellular virus,
adenain resides in an oxidized and dormant state, but becomes
activated again up on infection and re-entry into a reducing
cellular environment. Adenain eventually participates in the
final steps of the viral uncoating program, i.e., dissociation of
the viral DNA from the capsid at the nuclear pore complex, by
the digestion of pVI (Greber et al., 1996).
Using a biotinylated form of the specific DUB inhibitor Ub-
aldehyde as a probe, Balakirev et al. (2002) retrieved adenain
from a lysate of adenovirus-infected HeLa cells. They showed
that the enzyme accounted for a time-dependent increase in
global and, especially, nuclear deubiquitinating activity in late
phase adenovirus-infected cells compared to mock-infected
cells, as judged by the decline of the Ub conjugate pool
analyzed by Western blotting with anti-Ub antibodies (Bala-
kirev et al., 2002). Additionally, the authors overexpressed in
the same cell line hexahistidine-tagged Ub together with either
adenain or an autocleavable fusion of the enzyme to its
activating peptide cofactor pVIc, followed by enrichment of Ub
conjugates from cell lysates over a metal affinity resin. Anti-Ub
Western blotting of the resulting fractions demonstrated, again,
an overall reduction in Ub conjugates with both versions of the
transfected enzyme. Enzymatic in vitro assays with recombi-
nant purified adenain and substrate proteins, and chemically
synthesized pVIc peptide showed that adenain, indeed, exhibits
debranching activity against lysine-48 linked polyubiquitin and
could also process the ISG15 precursor protein, but not a fusion
of the yeast SUMO homolog Smt3 to the green fluorescent
protein. This specificity, seemingly, conflicts with the structural
classification of adenain as a member of the ULP family of
deSUMOylating enzymes (Balakirev et al., 2002) but agrees
250 Minireviewwell with the molecular binding site features of the enzyme
(reviewed by Sulea et al., 2006).
The described prevalence of adenain-dependent deubiquiti-
nation of nuclear proteins in infected cells (Balakirev et al.,
2002) is in accordance with the presence of adenain in this
subcellular compartment, where it is involved in virion
maturation. At the same time, however, activation of nuclear
adenain is thought to occur only inside the nascent virion
particle, with about 70 adenain-pVIc complexes remaining
incorporated per particle (Mangel et al., 2003). While this may
suggest that virion resident adenain deubiquitinates capsid
proteins, no change in the overall pattern of the anti-Ub staining
in comparison to nuclei of mock-infected cells was observed
(Balakirev et al., 2002), indicating that the overall decline in
nuclear Ub conjugates, for the most part, reflected deconjuga-
tion of cellular proteins. This could mean that activated adenain
partially escapes from nascent virions and acts on proteins in the
surrounding nucleoplasm (the possibility that nuclear adenain is
activated in a virion independent manner is considered below).
As already mentioned, besides HSV-1, adenoviruses belong
to the DNA viruses whose genomes associate with ND10.
Interestingly, ND10 in turn are associated with nuclear
aggresomes, sites that recruit chaperones, Ub, and proteasomes
and that may be specialized in protein degradation (reviewed by
Wileman, 2006). Moreover, ND10 have been proposed to
present passageways for proteins, including viral proteins that
are destined for proteasomal degradation in the proximity of
ND10 (Bailey and O'Hare, 2005; Hay, 2005). In this light, it is
tempting to speculate that deubiquitination by adenain safe-
guards the delivery of viral proteins to nascent capsids by
protecting them from proteasomal degradation at close-by
aggresomes, much as cellular USP7 is thought to stabilize ICP0
of HSV-1 (Boutell et al., 2005).
It is also noteworthy that the plasmid mediated over-
expression of adenain in HeLa cells, both with and without its
peptidic cofactor, resulted in an overall loss of cellular Ub
conjugates (Balakirev et al., 2002). The strong dependence of
adenain catalytic activity on cofactor complex formation and the
ability of the C-terminal sequence of the traditionally cytoplas-
mic protein actin to act as a cofactor (Brown and Mangel, 2004)
may suggest that predominantly cytoplasmic adenain activity
was detected in this experiment. Alternatively, a notable fraction
of adenain may have entered the nucleus together with actin
derived peptide cofactor. Actin itself has also been identified in
the nucleus as a component of protein complexes active in
various aspects of gene transcription (Grummt, 2006; Miralles
and Visa, 2006). Actin may therefore also be involved in a virion
independent stimulation of adenain activity in the nucleus.
Severe acute respiratory syndrome coronavirus papain-like
protease
After entry of the coronaviral single-stranded positive-sense
RNA genome into the cytoplasm, the viral replicase gene is
translated directly from it. Two coronaviral proteases, 3C-like
protease (3CLpro) and PLpro, are part of the replicase
polyprotein, the precursor of the altogether sixteen non-structural proteins (nsps) that form the viral RNA replication
complex (Snijder et al., 2003; Thiel et al., 2003). 3CLpro, on the
one hand, is contained in nsp5, and after autocleavage, releases
all downstream replicase subunits. PLpro, on the other hand,
originally referred to a domain of around 24 kDa within nsp3,
whose boundaries are defined by homology to the papain-fold
(Herold et al., 1999). PLpro processes the amino-proximal nsps
(Harcourt et al., 2004). In accordance with previous structural
bioinformatics prediction (Sulea et al., 2005), the crystal
structure of SARS-CoV PLpro recently established the
enzyme's membership in the USP family of DUBs (Ratia et
al., 2006). Additionally, it revealed an unexpected Ub-like
domain at the N-terminus of the PLpro catalytic core domain.
Ub-like domains are defined by a common β-grasp three-
dimensional structure (Kiel and Serrano, 2006). Within the
multidomain nsp3, PLpro is further preceded by an acidic
sequence forming the N-terminus of nsp3, a macro-domain with
ADP-ribose-1″-phosphatase activity, which is potentially
involved in viral RNA modification (Saikatendu et al., 2005),
and a so-called SARS unique domain (Snijder et al., 2003).
PLpro is followed by a hydrophobic domain with putative
transmembrane regions (Harcourt et al., 2004). PLpro cotran-
slationally liberates nsp1 to 3 in this order (Harcourt et al.,
2004). All three cleavage products become part of the repli-
cation complex, which is found bound to double-membrane
vesicles that are characterized by autophagosome markers
(Prentice et al., 2004). A more recent ultrastructural study,
however, points to the endoplasmic reticulum as the direct
origin of the membranes associated with SARS-CoV replication
complex, including nsp3 (Snijder et al., 2006).
SARS-CoV PLpro, which now refers to the enzyme's
catalytic core domain plus the N-terminal Ub-like domain, was
recombinantly expressed and purified (Barretto et al., 2005;
Lindner et al., 2005). As predicted based on the similarity of its
catalytic core domain to the corresponding domain of USP7
(Sulea et al., 2005), SARS-CoV PLpro displays DUB activity.
Specifically, it debranches lysine-48 polyubiquitin chains, very
efficiently hydrolyzes the general DUB substrate Ub-7-amino-4-
methylcoumarin (Ub-AMC) (Barretto et al., 2005; Lindner et al.,
2005), and exhibits ISG15 precursor processing activity
(Lindner et al., 2005). Although this proves the enzyme's
proficiency as a DUB in vitro, it is not clear whether SARS-CoV
PLpro can gain access to potential deubiquitination targets, other
than replicase polyprotein sequences themselves, during its
synthesis as part of the replicase polyprotein, cotranslational
autoprocessing, and incorporation into the membrane bound
replication complex. It is noteworthy that the synthesis of both
negative- and plus-strand coronavirus RNA requires ongoing
viral protein production (Kim et al., 1995; Perlman et al., 1986;
Sawicki and Sawicki, 1986), and it is conceivable that
concomitant deubiquitination by SARS-CoV PLpro protects
replicase subunits against proteasomal degradation.
Herpesvirus UL36USP
Prompted by the known interaction of ICP0 with cellular
USP7, Ploegh and coworkers made use of the active-site
251Minireviewdirected probe HAUbVME, mentioned above, to monitor DUB
activity in lysates of primary fibroblasts infected with HSV-1
(Kattenhorn et al., 2005). A major HAUb-adduct corresponding
to an ∼47-kDa protein occurred late in infection and persisted.
The protein was identified as N-terminal fragment of the
essential large (3164 amino acid residues) tegument protein
UL36 (also called VP1/2 or ICP1/2). Further labeling attempts
with similar Ubl probes, and in vitro enzymatic assays using a
533 residues recombinant N-terminal fragment of UL36,
established that the enzyme, baptized UL36USP, is specific for
Ub, but exhibits relatively low catalytic efficiency. Recombi-
nant HSV-1 UL36USP disassembled lysine-48 but not lysine-63
polyubiquitin chains which may implicate the enzyme in protein
stabilization (Kattenhorn et al., 2005).
Sequence alignment of UL36 homologs from α-, β-, and γ-
herpesvirus genomes identified a putative cysteine box around the
HAUbVME reactive cysteine residue, and a histidine box located
around 130 amino acids further downstream (Kattenhorn et al.,
2005).Although none of theUL36USP sequences shows similarity
to any knownDUB, the conservation of cysteine box and histidine
box motifs is characteristic of cysteine protease DUB families
(Amerik and Hochstrasser, 2004). In addition to HSV-1 (α-
subfamily), analogous labeling experiments confirmed the
presence of DUB activity and specificity for Ub in recombinant
UL36USP from EBV (γ-subfamily), and MCMVand HCMV (β-
subfamily) (Schlieker et al., 2005; Wang et al., 2006). The
sequence of the recombinant UL36USP variant examined for EBV
extended only little beyond the histidine boxmotif, demonstrating
that anN-terminal UL36 fragment of just under 22 kDa carries the
UL36USP specificity (Schlieker et al., 2005).
Wang et al. (2006) detected HAUbVME labeling of full-
length UL36 in HCMV, simian CMV (SCMV) and HSV-1-
infected fibroblasts. They also reported the detection of the 47-
kDa fragment of UL36 for HSV-1 previously described by
Kattenhorn et al. (2005) but ascribed its occurrence to uncon-
trolled proteolysis (Wang et al., 2006). The authors went ahead
to confirm catalytic activity in isolated wild-type and mutant
HCMV extracellular particles. Mutation of either the putative
catalytic cysteine or histidine residue abolished catalytic
activity, identifying UL36USP as the sole source of DUB acti-
vity in the virion. For additional mutants of several conserved
cysteine box and histidine box residues, the spread and dev-
elopment of cytopathic effects as well as virus yields in virus-
infected cells were wild-type like. Only the respective cysteine
and histidine mutants gave notably lower virus yields and
delayed the development of cytopathic effects. However, the
cysteine mutation caused no apparent changes during cell
infection as judged by electron microscopy. Overall, this
indicates that UL36USP is important for optimal HCMV
replication but is not essential in cell culture (Wang et al., 2006).
So far, we can only speculate on possible roles for UL36USP
considering the known implications of the large tegument
protein UL36, which according to earlier studies shows equal
cytoplasmic and nuclear distribution (McNabb and Courtney,
1992). UL36 was demonstrated to interact with a region of the
viral α sequence, which is required for cleavage and packaging
of the viral genome in the nucleus (Chou and Roizman, 1989)into icosahedral capsids (see Pomeranz et al., 2005, for a review
of the α-herpesvirus life cycle). Studies of α-herpesvirus-
infected cells using microscopic techniques coupled with pro-
tein labeling methods have led to two different theories that aim
at explaining how nucleocapsids exit the nucleus, obtain the
viral tegument, and acquire an envelop. They imply different
pathways for the capsid attachment of UL36, which is thought
to form the innermost, capsid-proximal layer of the tegument.
According to the more prevalent of the two theories (reviewed
by Mettenleiter, 2004; Mettenleiter et al., 2006), viral capsids
reach the cytoplasm by successive envelopment and de-
envelopment at the inner and outer membrane of the nuclear
envelope, respectively. Primary attachment of UL36 in the
cytoplasm then affords further assembly of inner tegument
proteins. The inner tegument subsequently coalesces with the
outer tegument, which assembles independently at future sites
of budding into the exocytic pathway, likely into the trans-Golgi
network (Mettenleiter, 2006). The alternative theory (Leuzinger
et al., 2005; Wild et al., 2005) assumes a dual pathway for
nuclear egress of capsids. Capsids may either undergo nuclear
envelopment followed by intraluminal transport to the Golgi, or
they may leave the nucleus directly through dilated nuclear
pores and afterwards bud from the cytoplasm into compart-
ments of the exocytic pathway. Here, the deposition of tegument
is thought to occur during the budding at the inner nuclear
membrane or at cytoplasmic membranes (Leuzinger et al.,
2005; Wild et al., 2005), hence presumably involving nuclear or
cytoplasmic UL36, respectively. It has however to be noted that
UL36 has not yet been detected as a component of virions inside
the lumen of the nuclear envelope (Mettenleiter and Minson,
2006). Wherever herpesvirus tegumentation occurs, tegument
proteins are known to engage in many complex protein–protein
interactions (reviewed by Mettenleiter, 2006). Yeast two-hybrid
analyses suggest that UL36 uses a domain downstream of
UL36USP to directly bind to UL37, another inner tegument
protein (Klupp et al., 2002; Vittone et al., 2005). Fusion of
Golgi derived vesicles with the plasma membrane eventually
releases infectious virions from the cell.
After infection by fusion of the viral envelope with the cell
membrane, UL36 initially stays associated with the capsid.
UL36 is in fact emerging as a main candidate among herpesviral
proteins that may dock incoming capsids to the dynein motor
during transport along microtubules (MTs) to the nuclear pores
(Granzow et al., 2005) and during retrograd axonal transport
(Antinone et al., 2006; Luxton et al., 2005). In this regard, it is
interesting to note that the minus end-directed transport of
misfolded proteins to the microtubule-organizing center during
aggresome formation was shown to require the interaction of the
dynein motor with the cellular DUB ataxin-3 (Burnett and
Pittman, 2005). As UL36USP, ataxin-3 debranches lysine-48
polyubiquitin chains, but possible targets of this activity during
retrograd transport are unknown. Last of all, a temperature
sensitive mutation in HSV-1 UL36 impeded the release of viral
DNA from the capsid into the nucleus at the nuclear pore
(Batterson et al., 1983).
Taken together, during herpesvirus infection UL36 report-
edly localizes to the nucleus, the cytoplasm, and the lumen of
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eventually part of the infectious virion, whose yield is reduced
by mutational inactivation of UL36USP. It remains speculative at
this point whether deubiquitination of viral or cellular proteins
by its UL36USP domain plays part in any of the processes that
have been associated with the presence of UL36 in these
locations, i.e., nucleocapsid formation, tegumentation, budding,
viral egress from and entry into cells, MT-dependent capsid
transport, and nuclear entry of the viral genome.
Viral ubiquitin and ubiquitin-like sequences
The genomes of some viruses encode Ub or Ub-like
sequences. The baculovirus Autographa californica nucleopo-
lyhedrovirus, for example, expresses a viral Ub precursor protein
during the late phase of infection (Guarino, 1990). Although
non-essential for replication in cell culture, the gene is required
for optimal virus production (Reilly and Guarino, 1996). The
baculoviral Ub is functional in protein conjugation in vitro but
inhibits the formation of more extended lysine-48 linked
polyubiquitin chains necessary for proteasomal targeting (Haas
et al., 1996). The authors speculated that this protects otherwise
short-lived viral proteins from proteasomal degradation.
Viruses also express Ub or Ub-like sequences as part of
multidomain polyproteins. Intriguingly, Ub and Ubls including
NEDD8, SUMO, and Atg8 homologs represent the most frequent
inserts in the polyprotein of several strains of bovine viral diarrhea
virus (BVDV), where their presence is associated with a viral
cytopathogenic phenotype (Baroth et al., 2000; Meyers et al.,
1998; Qi et al., 1998; Tautz et al., 1993). In fact, these inserts
function as polyprotein processing signals that allow cellular
proteases, presumably DUBs, to process the polyprotein at
positions corresponding to the precursors processing sites of the
respective cellular Ub or Ubl sequences. In the case of an Atg8
sequence insert in the BVDVisolate JaCP, the processing enzyme
was indeed identified as a specific cellular DUB, namely,
autophagin-1 (ATG4B) (Fricke et al., 2004).
Compared to Ub and Ubls, the already mentioned N-terminal
domain of SARS-CoV PLpro (Ratia et al., 2006) for example
represents a different but not less common type of Ub-like
domain (Kiel and Serrano, 2006). Here, the lack of a C-terminal
recognition sequence motif precludes proteolytic processing by
DUBs and subsequent conjugation to other molecules. Never-
theless, such intrinsic Ub-like domains also serve in mediating
protein–protein interactions in a variety of multidomain proteins
(see Kiel and Serrano, 2006, and references therein). These
include players of the UPS, such as specialized Ub receptors
(Elsasser and Finley, 2005), and last but not least DUBs (Nijman
et al., 2005; Zhu and Sulea, unpublished data). The domain
arrangement in SARS-CoV PLpro is in fact reminiscent of
USP14 and its homologs, where the Ub-like domain likewise
precedes the catalytic core domain. USP14 and its yeast
homolog Ubp6 both bind to the regulatory subunit of the
proteasome via their Ub-like domain which greatly stimulates
their catalytic activities (Hu et al., 2005; Schmidt et al., 2005).
Comparison of the crystal structures for the free and Ub bound
catalytic core domain of USP14 suggests that the enzyme isactivated by conformational translocation of two enzyme surface
loops, which block access of the Ub C-terminus to the active site
in the free enzyme (Hu et al., 2005). Proteasome binding may
promote this activation step. USP14 was further shown to
debranch lysine-48 linked polyubiquitin chains from the distal
end (Hu et al., 2005). USP14/Ubp6 is thought to prevent the
translocation of Ub from incoming substrates into the inner core
particle of the proteasome and to contribute to the homeostasis of
the cellular pool of free Ub (Schmidt et al., 2005). It is tempting
to speculate that the Ub-like domain of SARS-CoV PLpro may
similarly anchor the enzyme to a larger protein complex. There
is, however, no indication from the available crystal structure of
the free enzyme, like for USP14, that its catalytic activity may
require activation (Ratia et al., 2006).
Conclusions
The binding of ICP0 and EBNA1 to different domains of the
cellular DUB USP7 contributes to the maintenance of a
productive life cycle for HSV-1 and the establishment of
latency for EBV, respectively, representing the only well
established examples of viral interference with deubiquitination
so far. Interestingly, however, infection by EBV, HCMV, and
HPV modulates the activities of several cellular DUBs (Ovaa et
al., 2004; Rolén et al., 2006; Wang et al., 2006) the significance
of which remains to be established. DUBs, such as USP9X, for
instance, might be involved in β-catenin stabilization in latency
type III EBV-transformed B cells.
It will further be important to establish the roles of viral
deubiquitinating activities. Like USP7, the three recently
confirmed viral DUBs, adenain, SARS-CoV PLpro, and
herpesvirus UL36USP, all exhibit lysine-48 linked polyubiquitin
debranching activities. It is conceivable that viruses avail
themselves of this activity in order to stabilize viral gene products
or host cell proteins whose proteasomal degradation promotes
anti-viral responses such as IκB (Evans, 2005). The ability of
adenain and SARS-CoV PLpro to additionally cleave the ISG15
precursor protein has led to the speculation that these enzymes
mimic cellular USP18 (Sulea et al., 2006), a DUB with
delSGylating activity and a negative regulator of the IFN response
(Dao and Zhang, 2005). Recent data by Zhang and coworkers
(Malakhova et al., 2006) revealed, however, that USP18
attenuates JAK-STAT signaling, and thereby the type 1 IFN
response, in a non-enzymatic manner, i.e., by directly competing
with JAK1 for binding to the IFNAR2 subunit of the type 1 IFN
receptor. As for SARS-CoV PLpro, the importance of the
deubiquitinating activity of USP18 remains to be determined.
Table 1 summarizes the demonstrated and potential roles in
viral infection of both cellular and viral DUBs discussed thus
far. The review of the possible subcellular sites of action for the
three confirmed viral DUBs presented here suggests that their
deubiquitinating activities could, similar to the polyprotein
processing activities of adenain and SARS-CoV PLpro, also
contribute to more basic viral needs such as viral genome
replication and packaging, or viral egress and entry. Similar to
adenain (Greber et al., 1996), UL36USP may for example
exhibit digestive activity during the release of viral DNA from
Table 1
Demonstrated and potential roles of DUBs in virus infection
DUB Roles References
Demonstrated roles a
Adenovirus protease adenain Release of its own activating peptidic cofactor, maturation of capsid
precursor proteins, promotion of cell lysis by cleavage of cytokeratin 18 and
actin, support of viral uncoating, and DNA release by capsid protein digestion
at the nuclear pore
Mangel et al. (2003)
SARS-CoV PLpro Processing of nsp1 to 3 from the viral replicase polyprotein Harcourt et al. (2004)
Potential roles b
USP9X Stabilization of β-catenin in EBV-infected B cells Shackelford et al. (2003)
USP7 Impaired stabilization of p53 in the presence of EBNA1 of EBV leading
to apoptosis avoidance
Stabilization of ICP0 of HSV-1 supporting reactivation
of quiescent viral genomes and lytic infection
Hu et al. (2006);
Saridakis et al. (2005);
Sheng et al. (2006);
Boutell et al. (2005);
Canning et al. (2004)
Adenovirus protease adenain Stabilization of virion proteins, negative regulation of the IFN response c Balakirev et al. (2002)
SARS-CoV PLpro Stabilization of viral polyprotein sequences, negative regulation of the
IFN response c
Lindner et al. (2005);
Barretto et al. (2005)
Herpesvirus UL36USP Stabilization of viral proteins Kattenhorn et al. (2005)
a Among the viral enzymes with deubiquitinating activity, proteolytic roles during virus infection have only been demonstrated for the adenovirus protease adenain
and SARS-CoV PLpro. In both cases, however, they involve hydrolysis of polypeptides at regular peptide bonds by these enzymes and not isopeptide bond cleavage.
b DUBs have been proposed to benefit viral infection by stabilizing viral gene products or, selectively, cellular proteins by protecting them from proteasomal
degradation.
c The delSGylating activities of adenain and SARS-CoV PLpro may mimic USP18, a demonstrated negative regulator of the interferon response (Dao and Zhang,
2005). Yet, an isopeptidase independent mechanism for this function of USP18 was discovered recently (Malakhova et al., 2006), and the significance of its de-
ISGylating activity remains unclear.
253Minireviewthe capsid, explaining the prevention of this step in a tem-
perature sensitive mutant of HSV-1 UL36 (Batterson et al.,
1983).
The example of UL36USP of HCMV has shown that in-
fection of cell cultures with mutant viruses does not necessarily
cause a tangible phenotype. For adenain and SARS-CoV PLpro
it may prove difficult to dissect their essential functions in
polyprotein cleavage from the significance of their DUB
activities. For SARS-CoV, the actual importance of the nsp1/
2, nsp2/3, and nsp3/4 cleavages carried out by the PLpro is still
not clear. Nevertheless, in cell culture infection nsp1 appears to
suppress host gene expression by promoting host mRNA
degradation (Kamitani et al., 2006), and nsp2, although dispen-
sable, was shown to be required for optimal virus replication
(Graham et al., 2005). In order to, however, more comprehen-
sively study potential roles of cellular and viral DUBs in virus
pathogenicity, e.g., through the modulation of the host antiviral
immune responses, animal models of viral infection are needed
(cf. Arrode and Davrinche, 2003; Cantin et al., 1999; Cinatl
et al., 2005; Jogler et al., 2006).
The acquisition of Ub and Ubl sequences by strains of BVDV
as polyprotein processing signals is intriguing and suggests a
possible scenario for the evolutionary origin of viral DUBs. In
bovine cells, the essential processing of the Atg8 insert in the
BVDV isolate JaCP was demonstrated to be carried out by the
DUB ATG4B. This processing step also occurred when an Atg8
containing BVDV polyprotein sequence was recombinantly
expressed in avian, fish, and insect cells, as well as in a rabbit
reticulocyte lysate (Fricke et al., 2004). The utilization of a Ub or
Ubl sequence as polyprotein processing signal may present an
advantageous viral strategy because a newly infected host cell isvery likely to already express a DUB that can perform the
processing reaction. It is tempting to speculate that Ub or Ubl
sequence containing viruses originally have happened to insert
sequences of cellular DUBs into their genomes as functional
protein processing enzymes, thereby becoming independent of
the cellular enzymes. As a fitness advantage, this could have
enhanced the viral host cell spectrum.
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